ABT-263 is known to induce thrombopenia due to reduced platelet lifespan [50]; however, the next generation dual inhibitors of Bcl-XL and Bcl-2, such as AZD4320, have been reported to not induce dose-limiting thrombocytopenia [51] and, therefore, would be more suitable for a clinical application. This evidence concerns the gene BCL2 and Thrombocytopenia.